The KDF1 (Keratinocyte Differentiation Factor 1) antibody is a tool used to study the KDF1 protein, which plays a critical role in epithelial cell differentiation and tissue development. KDF1. also known as C14orf28 or FOJ1. is a transcription factor implicated in regulating keratinocyte maturation and skin barrier formation. It is primarily expressed in stratified squamous epithelia, including the epidermis, oral mucosa, and esophagus. Research suggests KDF1 interacts with signaling pathways like Notch and Wnt, influencing cell fate decisions during development and homeostasis.
Antibodies targeting KDF1 enable researchers to investigate its expression patterns, subcellular localization, and functional mechanisms in both normal and pathological contexts. These antibodies are commonly employed in techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Dysregulation of KDF1 has been linked to skin disorders, cancer progression (particularly squamous cell carcinoma), and congenital ectodermal defects. Recent studies highlight its potential as a biomarker or therapeutic target in dermatological and oncological research.
The development of KDF1 antibodies has advanced understanding of epithelial biology, offering insights into tissue repair, carcinogenesis, and genetic diseases affecting ectodermal derivatives. Commercial antibodies are typically validated for specificity using knockout cell lines or tissues to ensure reliable experimental outcomes. Ongoing research continues to explore KDF1's broader roles in development and disease.